A Rocket Pharmaceuticals gene therapy has reached the end of its regulatory journey before receiving an FDA decision. The company has withdrawn the submission for its therapeutic candidate for Fanconi anemia, a rare inherited blood disorder.

The voluntary withdrawal of the biologics license application (BLA) for mozafancogene autotemcel, known in earlier stages of development as RP-L201, follows a previously announced corporate reprioritization, the company said in a Friday regulatory filing . In July, Cranbury, New Jersey-based Rocket restructured operations , laying off about 30% of staff and turning the firm’s focus to cardiovascular programs it said offer the opportunity for creating near- and long-term value. With the restructuring, Rocket ceased any new internal spending on RP-L

See Full Page